 Connection
David Fox to Immunoconjugates
This is a "connection" page, showing publications David Fox has written about Immunoconjugates.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.426 |
|
|
|
-
Zhang L, Luo L, Chen JY, Singh R, Baldwin WM, Fox DA, Lindner DJ, Martin DF, Caspi RR, Lin F. A CD6-targeted antibody-drug conjugate as a potential therapy for T cell-mediated disorders. JCI Insight. 2023 12 08; 8(23).
Score: 0.179
-
Parameswaran N, Luo L, Zhang L, Chen J, DiFilippo FP, Androjna C, Fox DA, Ondrejka SL, Hsi ED, Jagadeesh D, Lindner DJ, Lin F. CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma. Leukemia. 2023 10; 37(10):2050-2057.
Score: 0.175
-
Gizinski AM, Fox DA, Sarkar S. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract Res Clin Rheumatol. 2010 Aug; 24(4):463-77.
Score: 0.071
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|